Status:

COMPLETED

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Lead Sponsor:

Jiangsu Province Centers for Disease Control and Prevention

Conditions:

Influenza

Eligibility:

All Genders

3-8 years

Phase:

PHASE4

Brief Summary

Routine annual influenza vaccination is recommended for all persons aged≥6 months who do not have contraindications. For those aged 6 monthsthrough 8 years who have previously received ≥2 total doses ...

Detailed Description

Subjects receive 2 dosed of quadrivalent influenza vaccine 4 weeks apart.Blood samples were obtained from children at 3 time points-before receiptof dose 1, 4 weeks after receipt of dose 1 and before ...

Eligibility Criteria

Inclusion

  • Aged 3-8 years old
  • Healthy subjects judged from medical history and clinical examination
  • Subjects themselves or their guardians able to understand and sign theinformed consent
  • Subjects themselves or their guardians can and will comply with therequirements of the protocol
  • Subjects have received ≥2 doses of trivalent or quadrivalent infuenzavaccine before enrollment (Doses need not have been received duringsame or consecutive seasons); Subjects have not received infuenzavaccine before enrollment
  • Subjects with temperature \<=37.0°C on axillary setting

Exclusion

  • Any prior administration of other research medicine/vaccine in last 30 days
  • Any prior administration of influenza vaccine in last 6 month
  • Any prior administration of immunodepressant or corticosteroids in last 3 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of any attenuated live vaccine in last 14 days
  • Any prior administration of subunit or inactivated vaccines in last 7 days
  • Subject who developed guillain-Barre syndrome post influenza vaccination
  • Subject who is allergic to any ingredient of the vaccine
  • Subject with acute febrile illness or infectious disease
  • Thrombocytopenia, blood coagulation disorder or bleeding difficulties withintramuscular injection
  • Subject with damaged or low immune function which has already beenknown
  • Subject with congenital heart disease or other birth defects unsuitable for vaccination.
  • Subject with respiratory diseases (including pneumonia, tuberculosis, severe asthma, etc.), heart, liver and kidney diseases, mental disorders, or chronic infections.
  • Any medical, psychological, social or other condition judged byinvestigator, that may interfere subject's compliance with the protocol

Key Trial Info

Start Date :

September 11 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 30 2022

Estimated Enrollment :

252 Patients enrolled

Trial Details

Trial ID

NCT05313893

Start Date

September 11 2021

End Date

May 30 2022

Last Update

August 17 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Donghai County Center for Disease Control and Prevention

Lianyungang, Jiangsu, China, 222300